Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-ad

Advertisement

ALUNBRIG® (Brigatinib)

May 28, 2020May 28, 2020 RR FDA Approvals
Lung Cancer: Non-Small Cell

The FDA on May 22, 2020 approved ALUNBRIG® for adult patients with Anaplastic Lymphoma Kinase (ALK)-positive metastatic Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test. ALUNBRIG® is a product of ARIAD Pharmaceuticals Inc.

Related Posts:

  • FDA Approves ALUNBRIG® for First Line Treatment of…
  • ALUNBRIG® (Brigatinib)
  • FDA Approves ALUNBRIG® for ALK Positive Non Small…

Post navigation

Dietary Supplement Use during Adjuvant Chemotherapy May Increase Risk for Breast Cancer Recurrence
OPDIVO® (Nivolumab) plus YERVOY® (Ipilimumab)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

FREE SUBSCRIPTION

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-Ad

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

ChemoPrescribe-Ad

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved